Quantcast

Latest Anthracyclines Stories

2010-05-18 00:30:00

SEATTLE, May 18 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTA) reported today preliminary cardiac safety results from a North American randomized phase II trial which substituted pixantrone for doxorubicin in the standard CHOP-R regimen. Called PIX203, the randomized trial compared CPOP-R directly to CHOP-R in the 1st line treatment of high risk patients with diffuse large B cell non-Hodgkin's lymphoma (DLBCL, NHL). While CHOP-R is considered the standard of...

2010-05-13 00:30:00

SEATTLE, May 13 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) (the "Company") today announced an agreement with the North Central Cancer Treatment Group (NCCTG) to conduct a phase II study of pixantrone in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens. The trial will be conducted through the NCCTG, a national network of cancer specialists at community...

2010-05-12 06:30:00

QUEBEC CITY, May 12 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrine therapy, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational New Drug (IND) application for its doxorubicin targeted conjugate compound, AEZS-108, in luteinizing hormone releasing hormone (LHRH) receptor positive urothelial (bladder) cancer. Following this...

2010-05-06 06:30:00

QUEBEC CITY, May 6 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), ("the Company") a late-stage drug development company specialized in oncology and endocrinology, today announced that it has received from the U.S. Food and Drug Administration (FDA), orphan-drug designation for AEZS-108, its doxorubicin targeted conjugate compound, for the treatment of ovarian cancer. AEZS-108 is currently in a Phase 2 trial in advanced ovarian and advanced endometrial cancer in...

2010-05-03 07:00:00

PRINCETON, N.J., May 3 /PRNewswire/ -- Celator Pharmaceuticals, Inc. today announced positive results from its Phase 2 study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus conventional cytarabine and daunorubicin (the "7+3" regimen) in patients, 60-75 years of age, with untreated acute myeloid leukemia (AML). The primary endpoint of the study, the rate of patients achieving a complete remission with CPX-351 compared to "7+3," achieved statistical significance. In addition,...

2010-04-22 07:00:00

PRINCETON, N.J., April 22 /PRNewswire/ -- Celator Pharmaceuticals today announced data from animal studies demonstrating the superior bone marrow uptake of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection, its lead clinical-stage program, as well as the enhanced circulation kinetics and efficacy of its preclinical hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation were presented at the 101st Annual Meeting of the American Association for Cancer Research in Washington, DC...

2010-04-21 00:30:00

SEATTLE, April 21 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced the European Medicines Agency (the "EMEA") Pediatric Committee (the "PDCO") recommended the Company submit an updated Pediatric Investigation Plan ("PIP") for pixantrone following discussions with the Company about the preclinical and clinical pixantrone data, including PIX301, and the desire to explore the potential benefits pixantrone may offer to children with...

2010-04-12 07:00:00

PRINCETON, N.J., April 12 /PRNewswire/ -- Celator Pharmaceuticals today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent covering the company's CombiPlex® technology platform (U.S. patent application 10/417,631), the basis for the company's product pipeline which includes two clinical-stage products for acute myeloid leukemia and colorectal cancer. CombiPlex is a unique approach in the development of combination...

2010-03-18 06:30:00

COLUMBIA, Md., March 18 /PRNewswire-FirstCall/ -- Celsion Corporation (Nasdaq: CLSN) today announced that an abstract about the Phase I/II trial of ThermoDox® in Recurrent Chest Wall Cancer (RCW) has been accepted for presentation at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting. The abstract presents the background, rationale, and design of the DIGNITY study which is ongoing and evaluating ThermoDox in combination with hyperthermia in women with...

2010-02-17 06:30:00

COLUMBIA, Md., Feb. 17 /PRNewswire-FirstCall/ -- Celsion Corporation (Nasdaq: CLSN), a leading oncology drug development company, today announced financial results for the fourth quarter and year ended December 31, 2009. Management also highlighted the progress made in clinical trials of ThermoDox®, Celsion's heat activated liposomal encapsulation of doxorubicin, including the Company's pivotal Phase III trial for the treatment of hepatocellular carcinoma (HCC), the most...


Word of the Day
humgruffin
  • A terrible or repulsive person.
Regarding the etymology of 'humgruffin,' the OED says (rather unhelpfully) that it's a 'made-up word.' We might guess that 'hum' comes from 'humbug' or possibly 'hum' meaning 'a disagreeable smell,' while 'gruffin' could be a combination of 'gruff' and 'griffin.'